building blockchain

Growing Houston blockchain company expands C-suite

Houston-based Data Gumbo has a new C-level exec to lead its growing sales team. Courtesy of Data Gumbo

After expanding into the Asian market last month, a Houston blockchain startup has grown its C-suite with the addition of a chief commercial officer to lead its sales team.

Data Gumbo Corp. has brought Bill Arend onto its team. Arend brings over 20 years of experience in software sales from the likes of Workday, Oracle. and Microsoft. The new hire comes at a time when Data Gumbo continues to expand, and, in March, the company brought on Indonesia-based client, Air Drilling Associates Indonesia-based client, Air Drilling Associates, a drilling and project management service provider.

"The opportunity abounds for Data Gumbo to help industry leaders to streamline current processes, eliminate errors, reduce contract leakage and save on costs," says Andrew Bruce, CEO of Data Gumbo, in a news release.

"Arend has the proven track record to support our mission in helping industrial players realize greater efficiencies and the leadership skills to scale our growing team as we continue to garner commercial momentum."

Data Gumbo's GumboNet is a robust blockchain network that provides automated contract execution for industrial clients. Beginning in the energy industry, Data Gumbo has since expanded into water management and construction.

"I am excited to join the Data Gumbo team to serve the market," Arrend says in the release. "There is a huge opportunity to provide industrial global enterprises a solution that drives down operating expenses by automating smart contracts."

Since its inception in 2016, the company has raised over $9.3 million in equity funding and grown its clientbase. The company, based out of The Cannon, operates as a blockchain-as-a-service model to improve efficiency for its industrial clients.

"In today's business climate, company's must look at their processes critically to find ways to improve productivity and cost efficiencies," Arend continues in the release. "Data Gumbo is well positioned to aid in that digital transformation for forward-looking companies."

Bill Arend has been named Data Gumbo's chief commercial officer. Photo courtesy of Data Gumbo

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News